SINOMAB BIO-B

3681
0.9600.52% ( +0.005 )
Delay Closed: Nov 16, 16:08:11

Overview

SINOMAB BIO-B (3681)

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatm...

Open
0.955
High
1.000
Low
0.955
Prev. Close
0.955
Volume
461.70K
Turnover
449.18K
Avg Price
0.973
Bid/Ask Ratio
-89.33%
Amplitude
4.71%
52wk High
2.190
Volume Ratio
0.39
Turnover Ratio
0.03%
52wk Low
0.955
HK Mkt Cap
1.33B
Market CapHKD
1.33B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.152
EPSDynamic
-0.212
EPSStatic
--
BVPS
0.30
P/B
3.20
HK Shares
1.39B
Dividend YieldTTM
--
DividendTTM
--
Shares
1.39B
Min lot size
300
Currency
HKD

SINOMAB BIO-B Analyst Rating

View more

Forecast & Rating

Jul 21, 2020
Price forecast
HK$2.99211.93%
Forecast & RatingStrong buy
1analysts
  • Strong buy100.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    SinoMab Bioscience staged a strong rebound today, surging 20.4% to close at HKD 1.300, with an intraday range of 23.1% from HKD 1.080 to HKD 1.330. The rally was driven by multiple recent positive developments: an annual loss narrowing 43.3% YoY to RMB 105 million, first cohort dosing completion for SM17 subcutaneous injection in China, and China IND approval to expand SM17 into inflammatory bowel disease. In Q4, EPS loss narrowed 51.7% YoY to HKD 0.0226, and net loss shrank 39.0% YoY. The stock closed above its MA20 (HKD 1.129) but remains 65.4% below the 52-week high of HKD 3.76, with a YTD decline of 6.5% and PB of 3.2x. However, the MA60 at HKD 1.341 still sits above the current price, suggesting the recovery remains incomplete.

News